FrancophonIA/ELRC3.0 huggingface dataset:
English: Table 1: Adverse reactions in combined phase 3, long-term extension studies and postmarketing experience in gout patients.
Slovenian: Preglednica 1: Neželeni učinki v kombiniranih študijah 3. faze, dolgoročne podaljšane študije in poročila v obdobju trženja pri bolnikih s protinom.
English: OUTER CARTON (BLISTERS AND BOTTLES)
Slovenian: ŠKATLA (PRETISNI OMOTI IN PLASTENKE)
English: Inducers of glucuronidation
Slovenian: Induktorji glukuronidacije
English: • dizziness, numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia)
Slovenian: • omotičnost, občutek odrevenelosti ali ščemenja, zmanjšano ali spremenjeno zaznavanje (hipoestezija, hemipareza ali parestezija) sprememba čuta za okušanje, zmanjšanje občutka za vonj (hiposmija),
English: The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs.
Slovenian: Poročila raziskovalcev o srčno-žilnih dogodkih APTC v kombiniranih študijah 3. faze (APEX, FACT in CONFIRMS študijah) so bila 0,7 v primerjavi z 0,6 dogodka na 100 bolniških let.
English: An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly more efficacious in lowering serum urate levels to < 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied).
Slovenian: Analiza pri bolnikih s protinom in okvaro ledvic je bila nato določena v študiji CONFIRMS in pokazala, da je bil febuksostat statistično pomembno učinkovitejši pri zmanjševanju serumskih ravni sečne kisline na < 6 mg/dl v primerjavi s 300 mg/200 mg alopurinola pri bolnikih s protinom in blago do zmerno okvaro ledvic (65 % bolnikov).
English: Following multiple doses of 80 mg of febuxostat in patients with mild, moderate or severe renal impairment, the Cmax of febuxostat did not change, relative to subjects with normal renal function.
Slovenian: Po večkratnih odmerkih 80 mg febuksostata pri bolnikih z blago, zmerno ali hudo ledvično okvaro, se vrednost Cmax febuksostata ni spremenila v primerjavi z osebami z normalnim delovanjem ledvic.
English: In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo.
Slovenian: V študiji na zdravih prostovoljcih sočasno jemanje 120 mg febuksostata štirikrat na dan in enkratnega 4 mg peroralnega odmerka rosiglitazona ni imelo nobenega farmakokinetičnega učinka na rosiglitazon in njegove Ndemetilrosiglitazon presnovke, kar nakazuje, da febuksostat ni zaviralec encima CYP2C8 in vivo.
English: Reduction in serum uric acid level to <6.0 mg/dL (357 µmol/L) was noted by the Week 2 visit and was maintained throughout treatment.
Slovenian: Znižanje vrednosti sečne kisline v serumu na < 6,0 mg/dl (357 µmol/l) so opazili pri obisku v 2. tednu, ohranilo pa se je ves čas zdravljenja.
English: Atrial fibrillation, palpitations, ECG abnormal Rare
Slovenian: Občasni atrijska fibrilacija, palpitacije, nenormalni EKG Redki nenadna kardialna smrt*
English: The Cmax and AUC of active metabolites increased up to 2- and 4-fold, respectively.
Slovenian: Cmax aktivnih presnovkov se je povišala za 2-krat in AUC za 4-krat.
English: Febuxostat Mylan tablets contain lactose.
Slovenian: Tablete zdravila Febuksostat Mylan vsebujejo laktozo.
English: • erectile difficulties
Slovenian: • težave z erekcijo.
English: Marketing Authorisation Holder Mylan S.A.S.
Slovenian: Imetnik dovoljenja za promet z zdravilom Mylan S.A.S.
English: These adverse reactions were mostly mild or moderate in severity.
Slovenian: Ti neželeni učinki so bili glede na resnost v glavnem blagi do zmerni.
English: In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department.
Slovenian: Če ste vzeli večji odmerek zdravila Febuksostat Mylan, kot bi smeli V primeru nenamerno vzetega prevelikega odmerka se o tem, kaj morate storiti, posvetujte s svojim zdravnikom ali pojdite v najbližji urgentni oddelek za nezgode in nujne primere.
English: Uncommon Dyspnoea, bronchitis, upper respiratory tract infection, cough
Slovenian: Občasni dispneja, bronhitis, okužba zgornjih dihal, kašelj
English: 28 film-coated tablets 84 film-coated tablets
Slovenian: 28 filmsko obloženih tablet 84 filmsko obloženih tablet
English: Co-administration of febuxostat 80 mg and theophylline 400 mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section 4.5).
Slovenian: Ob sočasnem jemanju 80 mg febuksostata in 400 mg teofilina v enkratnem odmerku pri zdravih prostovoljcih ni bilo nikakršnih farmakokinetičnih interakcij (glejte poglavje 4.5).
English: No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups.
Slovenian: Razlik v deležih bolnikov, ki so potrebovali zdravljenje zaradi izbruhov protina, v skupinah z 80 mg in 40 mg febuksostata niso opazili.
English: No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).
Slovenian: Študij pri bolnikih s hudo okvaro jeter (razred C po Child-Pughu) niso izvedli.
English: Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).
Slovenian: Zdravilo Febuksostat Mylan je indicirano za preventivo in zdravljenje hiperurikemije pri odraslih bolnikih, pri katerih poteka zdravljenje hematološkega malignega obolenja s srednje visokim do visokim tveganjem nastanka sindroma tumorske lize (TLS - Tumor Lysis Syndrome) s kemoterapijo.
English: When chemotherapy is given, cancer cells are destroyed, and uric acid levels increase in the blood accordingly, unless the formation of uric acid is prevented.
Slovenian: Rakaste celice se med kemoterapijo razkrojijo, posledično pa se poveča raven sečne kisline v krvi razen, če se prekine tvorba sečne kisline.
English: To achieve sUA less than 6 mg/dL, the dose of febuxostat was titrated from 40 mg up to 80 mg (regardless of renal function) and the dose of allopurinol was titrated in 100 mg increments from 300 to 600 mg in patients with normal renal function and mild renal impairment and from 200 to 400 mg in patients with moderate renal impairment.
Slovenian: S ciljem, da se doseže vrednost sečne kisline v serumu pod 6 mg/dl, je bil odmerek febuksostata titriran od 40 mg do največ 80 mg (ne glede na ledvično funkcijo), odmerek v velikosti 100 mg alopurinola pa je bil dan v korakih od 300 do 600 mg pri bolnikih z normalno ledvično funkcijo in blago ledvično okvaro ter po korakih od 200 do 400 mg pri bolnikih z zmerno ledvično okvaro.
English: APEX Study: The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study.
Slovenian: Študija APEX: Z alopurinolom in s placebom kontrolirana študija učinkovitosti febuksostata (Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat - APEX) je bila randomizirana, dvojno slepa, multicentrična, 28-tedenska študija 3. faze.
English: Febuxostat Mylan tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body.
Slovenian: Tablete Febuksostat Mylan vsebujejo zdravilno učinkovino febuksostat in jih uporabljamo za zdravljenje protina, ki je povezan z izločanjem substance, ki se imenuje sečna kislina (urati) v telesu.
English: • potentially life-threatening skin rashes characterised by formation of blisters and shedding of the skin and inner surfaces of body cavities, e.g. mouth and genitals, painful ulcers in the mouth and/or genital areas, accompanied by fever, sore throat and fatigue (Stevens- Johnson Syndrome/ Toxic Epidermal Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (drug reaction with eosinophilia and systemic symptoms-DRESS) (see section 2)
Slovenian: • potencialno življenjsko nevarni kožni izpuščaji, za katere je značilna tvorba mehurčkov, luščenje kože in notranjih površin telesnih votlin, npr. ust in spolovil, boleče razjede v območju ust in/ali spolovil, ki jih spremlja povišana telesna temperatura, boleče grlo in utrujenost (Stevens-Johnsonov sindrom/toksična epidermalna nekroliza) ali povečani limfatični vozliči, povečanje jeter, hepatitis (vse do jetrne odpovedi), povečanje števila belih krvničk v krvi (reakcija na zdravilo z eozinofilijo in sistemskim simptomom - sindrom DRESS) (glejte poglavje 2)
English: Hypromellose Titanium dioxide (E171) Ethylcellulose Iron oxide yellow (E172) Triacetin
Slovenian: Obloga tablete hipromeloza titanov dioksid (E171) etil celuloza rumeni železov oksid (E172) triacetin črni železov oksid (E172)
English: FACT Study: The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study.
Slovenian: Študija FACT: Z alopurinolom kontrolirana študija s febuksostatom (Febuxostat Allopurinol Controlled Trial - FACT) je bila randomizirana, dvojno slepa, multicentrična, 52-tedenska študija 3. faze.
English: Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation.
Slovenian: Zato se 1-2 tedna po uvedbi zdravljenja z močnimi zaviralci glukuronidacije priporoča nadzor sečne kisline v serumu.
English: Febuxostat Mylan should be taken by mouth and can be taken with or without food.
Slovenian: Zdravilo Febuksostat Mylan se jemlje peroralno, s hrano ali brez hrane.
English: Other medicines and Febuxostat Mylan
Slovenian: Druga zdravila in zdravilo Febuksostat Mylan
English: Febuxostat 240 mg
Slovenian: Febuksostat 240 mg
English: Febuxostat Mylan tablets contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'.
Slovenian: Zdravilo Febuksostat Mylan vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ''brez natrija''.
English: The recommended oral dose of Febuxostat Mylan is 80 mg once daily without regard to food.
Slovenian: Priporočeni peroralni dnevni odmerek zdravila Febuksostat Mylan je 80 mg enkrat na dan ne glede na uživanje hrane.
English: Febuxostat Mylan tablets contain lactose (a type of sugar).
Slovenian: Zdravilo Febuksostat Mylan vsebuje laktozo (vrsto sladkorja).
English: * Adverse reactions coming from post-marketing experience ** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.
Slovenian: ** Driska povzročena z zdravljenjem in nenormalni testi jetrne funkcije pri kombiniranih študijah 3. faze, so bili pogostejši pri bolnikih, ki so se sočasno zdravili s kolhicinom.
English: In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble.
Slovenian: Pri nekaterih ljudeh se lahko koncentracija sečne kisline v krvi poveča in če postane previsoka, sečna kislina ni več topna.
English: Components of a multipack, can't be sold separately.
Slovenian: 42 filmsko obloženih tablet Sestavni del večkratnega pakiranja, ločeno ni v prodaji.
English: No data is available regarding the safety of febuxostat during other cytotoxic therapy.
Slovenian: Podatkov o varnosti uporabe febuksostata med zdravljenjem z drugimi citotoksini ni.
English: A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists' Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies).
Slovenian: Poročila raziskovalcev kažejo na številčno večjo pojavnost srčno-žilnih dogodkov APTC (opredeljenih kot končne točke v raziskavi Anti-Platelet Trialists' Collaboration (APTC), vključno s srčno-žilno smrtjo, miokardnim infarktom brez smrtnega izida, možgansko kapjo brez smrtnega izida) v skupini, zdravljeni s febuksostatom, v primerjavi s skupino, zdravljeno z alopurinolom v študijah APEX in FACT (1,3 v primerjavi z 0,3 dogodka na 100 bolniških let ), ne pa tudi v študiji CONFIRMS (glejte poglavje 5.1 za podrobnejši opis študij).
English: In a study in healthy subjects, 120 mg febuxostat QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo.
Slovenian: V študiji pri zdravih prostovoljcih, ki so jemali febuksostat v odmerku 120 mg enkrat na dan, je prišlo do povprečno 22 % povečanja AUC dezipramina, substrata CYP2D6, kar kaže na potencialni šibek zaviralni učinek febuksostata na encim CYP2D6 in vivo.
English: Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia, and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis) (see section 4.4).
Slovenian: Preobčutljivostne reakcije na febuksostat so lahko povezane z naslednjimi simptomi: kožne reakcije, za katere je značilno: infiltriran makulopapulozen izpuščaj, generalizirani ali eksfoliativni izpuščaji, pa tudi razjede na koži, edem obraza, zvišana telesna temperatura, hematološke nepravilnosti kot je trombocitopenija in eozinofilija ter prizadetost enega ali več organov (jeter in ledvic z vključno tubulointersticijskim nefritisom) (glejte poglavje 4.4).
English: After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52).
Slovenian: Po 8 tednih preventivnega zdravljenja se je pojavnost večjega števila napadov protina zmanjšala in se postopoma zniževala (64 % in 70 % oseb je prejelo zdravljenje proti izbruhom protina v tednih od 8 do 52).
English: Gout flare prophylaxis is recommended (see section 4.2 and 4.4).
Slovenian: Za preprečevanje ponovnega zagona protina se priporoča preventivno zdravljenje (glejte poglavji 4.2 in 4.4).
English: Left untreated, larger deposits called tophi may form in and around joints.
Slovenian: Nezdravljeni izbruhi protina lahko povzročijo odlaganje večjih depozitov uratov v sklepih in okoli njih, ki se imenujejo tofi.
English: Drug interaction studies of febuxostat with drugs (except theophylline) that are metabolized by XO have not been performed in humans.
Slovenian: Študij medsebojnega delovanja febuksostata z zdravili (razen s teofilinom), ki se presnavljajo s ksantinsko oksidazo niso izvedli na ljudeh.
English: The efficacy of febuxostat was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study, described below) that were conducted in 4101 patients with hyperuricaemia and gout.
Slovenian: Učinkovitost febuksostata je bila dokazana v treh ključnih študijah 3. faze (dve ključni študiji APEX in FACT ter dodatna študija CONFIRMS, ki so opisane v nadaljevanju) pri 4.101 bolnikih s hiperurikemijo in protinom.
English: Lactose and Sodium content
Slovenian: Vsebnost laktoze in natrija
English: Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine as inhibition of xanthine oxidase by febuxostat may cause increased plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity.
Slovenian: Uporabe febuksostata se ne priporoča pri bolnikih, ki se sočasno zdravijo z merkaptopurinom/azatioprinom, saj lahko febuksostat z inhibicijo ksantinske oksidaze povzroči povečano plazemsko koncentracijo merkaptopurin/azatioprina, kar lahko povzroči hudo toksičnost.
English: Film-coated tablets
Slovenian: filmsko obložena tableta
English: Mercaptopurine/azathioprine
Slovenian: Merkaptopurin/azatioprin
English: Mean AUC sUA1-8 (mgxh/dl) was significantly lower with febuxostat (514.0 ± 225.71 vs 708.0 ± 234.42; least square means difference: -196.794 [95% confidence interval: -238.600 ; -154.988]; p < .0001).
Slovenian: Srednja AUC sUA1-8 (mgxh/dl) je bila značilno manjša pri uporabi febuksostata (514,0 ± 225,71 proti 708,0 ± 234,42; razlika povprečne vrednosti najmanjšega kvadrata: -196,794 [95% interval zaupanja: -238,600 ; -154.988]; p < 0,0001).
English: The primary endpoint in CARES was the time to first occurrence of MACE, a composite of nonfatal MI, non-fatal stroke, CV death and unstable angina with urgent coronary revascularization.
Slovenian: Primarni opazovani dogodek študije CARES je bil čas do prvega pojava MACE, ki je sestavljen iz miokardnega infarkta (MI) brez smrtnega izida, možganske kapi brez smrtnega izida, smrti zaradi srčno-žilnega vzroka in nestabilne angine pektoris z nujno koronarno revaskularizacijo.
English: Following multiple doses of 80 mg of febuxostat in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the Cmax and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function.
Slovenian: Po večkratnih odmerkih 80 mg febuksostata pri bolnikih z blago (razred A po Child-Pughu) ali zmerno (razred B po Child-Pughu) okvaro jeter se Cmax in AUC febuksostata in njegovih presnovkov nista pomembneje spremenili v primerjavi z osebami z normalnim delovanjem jeter.
English: Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).
Slovenian: Zdravljenje kronične hiperurikemije v primerih, ko je že prišlo do odlaganja kristalov urata (vključno s primeri, kjer so ali so kdaj prej bili prisotni tofi ali uratni artritis).
English: • yellowing of the skin (jaundice)
Slovenian: • rumenkasto obarvana koža (zlatenica),
English: Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatine increase, blood creatinine increase, haemoglobin decrease, blood urea increase, blood triglycerides increase, blood cholesterol increase, haematocritic decrease, blood lactate dehydrogenase increased, blood potassium increase
Slovenian: Pogosti zvišanje amilaze v krvi, znižanje števila trombocitov, zmanjšano število belih krvnih celic, zmanjšano število limfocitov, povečane vrednosti kreatina v krvi, povečane vrednosti kreatinina v krvi, znižanje vrednosti hemoglobina, povečanje koncentracije sečnine v krvi, zvišanje vrednosti trigliceridov v krvi, zvišanje ravni holesterola v krvi, zmanjšan hematokrit, povečanje laktat dehidrogenaze v krvi, povečanje kalija v krvi
English: If you miss a dose of Febuxostat Mylan take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time.
Slovenian: Če ste pozabili vzeti zdravilo Febuksostat Mylan Če pozabite vzeti odmerek zdravila Febuksostat Mylan, ga vzemite takoj, ko se spomnite, razen če je skoraj čas za naslednji odmerek.
English: Febuxostat Mylan is indicated in adults.
Slovenian: Zdravilo Febuksostat Mylan je indicirano pri odraslih.
English: After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 µg/mL, and 5.05.3 µg/mL, respectively.
Slovenian: Po enkratnem ali ponavljajočem se peroralnem odmerku 80 mg enkrat na dan je Cmax približno 2,8-3,2 µg/ml, pri odmerku 120 mg pa 5,05,3 µg/ml.
English: Gout flare prophylaxis of at least 6 months is recommended (see section 4.4).
Slovenian: Za preprečevanje ponovnega zagona protina je priporočeno preventivno zdravljenje vsaj 6 mesecev (glejte poglavje 4.4).
English: Arthralgia, arthritis, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle tightness, bursitis Rare
Slovenian: Občasni artralgija, artritis, mialgija, mišično-skeletna bolečina, mišična oslabelost, mišični krči, mišična togost, burzitis Redki rabdomioliza*, togost sklepov, togost skeletnega mišičja
English: Thus, co-administration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.
Slovenian: Tako pri sočasni uporabi febuksostata z rosiglitazonom ali drugimi substrati CYP2C8 ni za pričakovati potrebe po prilagoditvi odmerka učinkovin.
English: Rare side effects (may affect up to 1 in 1,000 people) are:
Slovenian: Redki neželeni učinki (pojavijo se pri 1 od 1.000 bolnikov) so:
English: Patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome treated with febuxostat should be under cardiac monitoring as clinically appropriate.
Slovenian: Bolnike, ki se zdravijo s febuksostatom in pri katerih poteka zdravljenje hematološkega malignega obolenja s srednje visokim do visokim tveganjem nastanka sindroma tumorske lize (TLS) s kemoterapijo, je potrebno skrbno spremljati delovanje srca, kot je klinično ustrezno.
English: Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro.
Slovenian: Pokazalo se je, da je febuksostat šibak zaviralec encima CYP2C8 in vitro.
English: As there has been no experience with febuxostat, its use in these populations is not recommended.
Slovenian: Ker z uporabo febuksostata pri teh bolnikih ni izkušenj, se uporaba pri tej skupini bolnikov ne priporoča.
English: EXP After first opening use within 180 days
Slovenian: EXP: Po odprtju porabite v roku 180 dni.
English: Primary endpoint in the sub-group of patients with renal impairment The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and ≤2.0 mg/dL).
Slovenian: Primarni opazovani dogodek v podskupini bolnikov z okvaro delovanja ledvic V študiji APEX je bila ocenjena učinkovitost pri 40 bolnikih z okvaro delovanja ledvic (tj. izhodiščna vrednost kreatinina v serumu > 1,5 mg/dl in≤ 2,0 mg/dl).
English: No data comparing febuxostat with rasburicase are currently available.
Slovenian: Na voljo ni podatkov, ki bi primerjali febuksostat z razburikazo.
English: Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).
Slovenian: Zdravilo Febuksostat Mylan je indicirano za zdravljenje kronične hiperurikemije v primerih, ko je že prišlo do odlaganja kristalov urata (vključno s primeri, kjer so ali so kdaj prej bili prisotni tofi ali uratni artritis).
English: However, weight-corrected Cmax and AUC were similar between the genders.
Slovenian: Korigirane vrednosti Cmax in AUC glede na telesno maso so pri obeh spolih podobne.
English: No data is available for febuxostat 120 mg.
Slovenian: Na voljo ni podatkov za 120 mg febuksostata.
English: In healthy subjects, maximum plasma concentrations (Cmax) and area under the plasma concentration time curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat.
Slovenian: Pri zdravih prostovoljcih so se največje plazemske koncentracije (Cmax) in površine pod krivuljo plazemskih koncentracij v odvisnosti od časa (AUC) febuksostata po enkratnem in večkratnih odmerkih 10 mg do 120 mg povečevale sorazmerno z odmerkom.
English: 4.2 Posology and method of administration
Slovenian: 4.2 Odmerjanje in način uporabe Odmerjanje